Cargando…

Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer

A dose of 200 mg 3‐weekly of pembrolizumab was approved by the Food and Drug Administration (FDA) as treatment for advanced non‐small cell lung cancer (NSCLC) without oncogenic drivers. This is despite evidence showing no difference in efficacy with 2 mg/kg. Our study aimed to assess the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Low, Jia Li, Huang, Yiqing, Sooi, Kenneth, Ang, Yvonne, Chan, Zhi Yao, Spencer, Katie, Jeyasekharan, Anand Devaprasath, Sundar, Raghav, Goh, Boon Cher, Soo, Ross, Yong, Wei Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545741/ https://www.ncbi.nlm.nih.gov/pubmed/33634869 http://dx.doi.org/10.1002/ijc.33534

Ejemplares similares

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study
por: Wu, Yi‐Long, et al.
Publicado: (2020)

Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank)
por: Low, Jia Li, et al.
Publicado: (2022)

Now or later: Health impacts of delaying single‐dose HPV vaccine implementation in a high‐burden setting
por: Burger, Emily A., et al.
Publicado: (2022)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018)

Special issue “The advance of solid tumor research in China”: Participants with a family history of cancer have a higher participation rate in low‐dose computed tomography for lung cancer screening
por: Guo, Lan‐Wei, et al.
Publicado: (2022)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
por: Li, Jingmei, et al.
Publicado: (2018)

Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals
por: Xu, Junjie, et al.
Publicado: (2016)

Use of thermo‐coagulation as an alternative treatment modality in a ‘screen‐and‐treat’ programme of cervical screening in rural Malawi
por: Campbell, Christine, et al.
Publicado: (2016)

Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma
por: Wilkinson, Michelle J., et al.
Publicado: (2016)

Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
por: Pan, Zhenyu, et al.
Publicado: (2016)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
por: Kato, Junko, et al.
Publicado: (2016)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016)

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016)

Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women
por: Gultekin, Murat, et al.
Publicado: (2017)

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
por: Luo, Yong, et al.
Publicado: (2018)

The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated‐recombinant arginase I BCT‐100
por: De Santo, Carmela, et al.
Publicado: (2017)

Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study
por: Sun, Zimin, et al.
Publicado: (2018)

Near‐infrared photoimmunotherapy targeting EGFR—Shedding new light on glioblastoma treatment
por: Burley, Thomas A., et al.
Publicado: (2018)

Bepridil exhibits anti‐leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia
por: Baldoni, Stefano, et al.
Publicado: (2018)

The effect of FASN inhibition on the growth and metabolism of a cisplatin‐resistant ovarian carcinoma model
por: Papaevangelou, Efthymia, et al.
Publicado: (2018)

Cervical cancer risk in HPV‐positive women after a negative FAM19A4/mir124‐2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow‐up
por: De Strooper, Lise M.A., et al.
Publicado: (2018)

Aneustat (OMN54) has aerobic glycolysis‐inhibitory activity and also immunomodulatory activity as indicated by a first‐generation PDX prostate cancer model
por: Qu, Sifeng, et al.
Publicado: (2018)

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
por: Mondal, Susmita, et al.
Publicado: (2018)

Screen‐detected and interval colorectal cancers in England: Associations with lifestyle and other factors in women in a large UK prospective cohort
por: Blanks, Roger, et al.
Publicado: (2019)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials
por: Modest, Dominik Paul, et al.
Publicado: (2019)

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

Modeling and multiscale characterization of the quantitative imaging based fibrosis index reveals pathophysiological, transcriptome and proteomic correlates of lung fibrosis induced by fractionated irradiation
por: Zhou, Cheng, et al.
Publicado: (2019)

Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
por: Park, Ye‐Lim, et al.
Publicado: (2018)

Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology‐screened referral population
por: Leeman, Annemiek, et al.
Publicado: (2018)

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial
por: Tesch, Hans, et al.
Publicado: (2018)

Systematic reviews as a ‘lens of evidence’: Determinants of benefits and harms of breast cancer screening
por: Mandrik, Olena, et al.
Publicado: (2019)

Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo
por: Liu, Xuejiao, et al.
Publicado: (2019)

The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk
por: MacKintosh, Michelle L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n8qaq1vkqs6c2rdq6joatl82oc